Actualités

Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale.

Kerckhove N, Delage N, Bertin C, Kuhn E, Cantagrel N, Vigneau C, Delorme J, Lambert C, Pereira B, Chenaf C, Authier N; Poma Network. Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale. Front Pharmacol. 2022 Sep 5;13:947006. doi: …

Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale. Lire la suite »

What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion

Carton L, Icick R, Weibel S, Dematteis M, Kammerer E, Batisse A, Rolland B. What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion. Expert Rev Clin Pharmacol. 2022 Aug 18:1-5. doi: 10.1080/17512433.2022.2112950. Epub ahead of print. PMID: 35959655.

Minors and young adult’s hospitalizations after « chimique » consumption in Mayotte Island: Which substances are involved?

Goncalves R, Peyré A, Castaing N, Beeken T, Olivier S, Combe P, Miremont-Salamé G, Titier K, Molimard M, Daveluy A. Minors and young adult’s hospitalizations after « chimique » consumption in Mayotte Island: Which substances are involved? Therapie. 2022 Aug 1:S0040-5957(22)00124-X. doi: 10.1016/j.therap.2022.07.007. Epub ahead of print. PMID: 36064627.

Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users.

Laforgue EJ, Rousselet M, Claudon A, Aquizerate A, Jolliet P, Istvan M, Victorri-Vigneau C. Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users. Int J Environ Res Public Health. 2022 Jul 22;19(15):8920. doi: 10.3390/ijerph19158920. PMID: 35897285; PMCID: PMC9331950.

Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19

Dumoulin C, Ong N, Ramaroson H, Létinier L, Miremont-Salamé G, Gilleron V, Daveluy A, Perino J. Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19 [Hospitalizations after substance use during the COVID-19 pandemic]. Therapie. 2022 Jun 30:S0040-5957(22)00108-1. French. doi: 10.1016/j.therap.2022.06.003. Epub ahead of print. PMID: 35908997;  PMCID: PMC9329723. 

Communiqué – Augmentation des complications sanitaires graves associées à l’usage non médical du protoxyde d’azote en France

Communiqué de l’Association Française des Centres d’Addictovigilance du 23 juin 2022. L’Association Française des Centres d’Addictovigilance alerte sur les caractéristiques cliniques et l’ampleur des complications sanitaires graves avec l’usage non médical du protoxyde d’azote. Lisez le communiqué complet ci-dessous :

Abuse and misuse of second-generation antipsychotics: an analysis using VigiBase TM , the World Health Organisation pharmacovigilance database

Roy S, Charreteur R, Peries M, Kheloufi F, Eiden C, Nagot N, Donnadieu-Rigole H, Micallef J, Peyrière H. Abuse and misuse of second-generation antipsychotics: an analysis using VigiBase TM , the World Health Organisation pharmacovigilance database. Br J Clin Pharmacol. 2022 May 27. doi: 10.1111/bcp.15420. Epub ahead of print. PMID: 35633029.  

Retour en haut